Form 4: Vir Biotechnology CEO Marianne De Backer Transfers Shares for Tax Planning

Marianne De Backer, CEO of Vir Biotechnology, reports a transfer of common stock for tax planning purposes, with no change in overall beneficial ownership.

Summary

• On June 12, 2024, Marianne De Backer, CEO of Vir Biotechnology, executed a transaction involving the company's common stock.
• The transaction involved the transfer of 53,118 shares of common stock.
• These shares were transferred without consideration for tax planning purposes.
• Following the transaction, De Backer directly owns 625,339 shares.
• De Backer also indirectly owns 53,118 shares through the Ureel-De Backer Family Trust, where she and her spouse serve as Trustees.

Sentiment

Score: 7

Explanation: The document is a neutral regulatory filing. The transaction is for tax planning purposes and doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a transfer of shares for tax planning, which is a common practice among executives.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on stakeholders as it is a transfer for tax planning purposes and does not change the overall beneficial ownership of the reporting person.

Key Dates